Halia Therapeutics Partners with Southern Star Research to Launch Phase 1 Trial for Neurodegenerative Drug

• Halia Therapeutics has partnered with Southern Star Research to initiate a Phase 1 clinical trial for their LRRK2 inhibitor, HT-4253.

• The trial, set to begin in Q4 2024, aims to address neurodegenerative diseases, including Alzheimer’s Disease.

Halia Therapeutics, Inc. has entered a strategic collaboration with Southern Star Research Pty Ltd, an Australian contract research organisation (CRO), to launch a Phase 1 clinical trial for its LRRK2 inhibitor, HT-4253. This collaboration signifies a crucial step in the development of new treatments for neurodegenerative diseases such as Alzheimer’s Disease.

The trial is expected to commence in the fourth quarter of 2024, with initial results anticipated in 2025. Halia’s partnership with Southern Star Research is aimed at leveraging the CRO’s expertise in clinical research to ensure the trial’s success.

Dr. David J Bearss, CEO of Halia Therapeutics, expressed the importance of this partnership, noting that Southern Star Research’s commitment to clinical excellence aligns with Halia’s mission to develop groundbreaking therapies targeting the root causes of neurodegeneration.

David Lloyd, Managing Director of Southern Star Research, shared his enthusiasm for the collaboration, highlighting the potential impact of HT-4253 on addressing the significant unmet needs in neurodegenerative disease treatment.

As the companies prepare for the trial, they remain focused on maintaining the highest standards of safety, compliance, and scientific integrity, driven by a shared goal of bringing hope to patients worldwide suffering from neurodegenerative conditions.